Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTG-300 in Hereditary Hemochromatosis
NCT04202965Phase 2Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Mar 2020
- Primary completion
- Oct 2021
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of rusfertide in hereditary hemochromatosis (HH), sponsored by Protagonist Therapeutics, Inc.. Started Mar 2020; status: completed.
02
Drugs
rusfertide
03
Conditions
hereditary hemochromatosis (HH)
Beyond the preview
Go deeper on NCT04202965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202965.